Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 56, 66-71, January 1, 1996]
© 1996 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Osborne, M. R.
Right arrow Articles by Phillips, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Osborne, M. R.
Right arrow Articles by Phillips, D. H.

Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liver DNA of Rats Treated with Tamoxifen1

Martin R. Osborne2, Alan Hewer, Ian R. Hardcastle, Paul L. Carmichael and David H. Phillips

Section of Molecular Carcinogenesis, Haddow Laboratories [M. R. O., A. H., P. L. C., D. H. P.] and CRC Centre for Cancer Therapeutics [I. R. H.], Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, England

The antiestrogenic drug tamoxifen induces liver tumors in rats by a genotoxic mechanism. The key step has been proposed to be the formation of a reactive carbocation from the metabolite {alpha}-hydroxytamoxifen. This compound reacts with DNA in vitro to a small extent (1 in 105 DNA bases), giving products identical to those found in rat liver cells treated with tamoxifen. Now we have prepared the more reactive {alpha}-acetoxytamoxifen, which reacts with DNA in vitro to a much greater extent (1 in 50 bases). The products of this reaction were subjected to 32P postlabeling and shown by both TLC and reverse-phase liquid chromatography to be identical to those isolated from DNA treated with {alpha}-hydroxytamoxifen and to those found in the liver DNA of rat hepatocytes treated with tamoxifen or of the livers of rats treated with tamoxifen. The major product was also isolated as the nucleoside and characterized by UV, mass, and proton magnetic resonance spectroscopy. It is an adduct of tamoxifen and deoxyguanosine in which the {alpha} position of tamoxifen is linked covalently to the exocyclic amino group of deoxyguanosine.

1 This work was supported by grants from the Cancer Research Campaign, United Kingdom.

2 To whom requests for reprints should be addressed.

Received 7/27/95. Accepted 10/31/95.




This article has been cited by other articles:


Home page
Cancer Res.Home page
K. Brown, E. M. Tompkins, D. J. Boocock, E. A. Martin, P. B. Farmer, K. W. Turteltaub, E. Ubick, D. Hemingway, E. Horner-Glister, and I. N.H. White
Tamoxifen Forms DNA Adducts in Human Colon after Administration of a Single [14C]-Labeled Therapeutic Dose
Cancer Res., July 15, 2007; 67(14): 6995 - 7002.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. Y. Kim, N. Suzuki, Y. R. S. Laxmi, and S. Shibutani
INEFFICIENT REPAIR OF TAMOXIFEN-DNA ADDUCTS IN RATS AND MICE
Drug Metab. Dispos., February 1, 2006; 34(2): 311 - 317.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. Y. Kim, Y. R. S. Laxmi, N. Suzuki, K. Ogura, T. Watabe, M. W. Duffel, and S. Shibutani
FORMATION OF TAMOXIFEN-DNA ADDUCTS VIA O-SULFONATION, NOT O-ACETYLATION, OF {alpha}-HYDROXYTAMOXIFEN IN RAT AND HUMAN LIVERS
Drug Metab. Dispos., November 1, 2005; 33(11): 1673 - 1678.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
D. H. Phillips, A. Hewer, M. R. Osborne, K. J. Cole, C. Churchill, and V. M. Arlt
Organ specificity of DNA adduct formation by tamoxifen and {alpha}-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment
Mutagenesis, July 1, 2005; 20(4): 297 - 303.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
L. J. Schild, D. H. Phillips, M. R. Osborne, A. Hewer, F. A. Beland, M. I. Churchwell, K. Brown, M. Gaskell, E. Wright, and M. C. Poirier
Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods
Mutagenesis, March 1, 2005; 20(2): 115 - 124.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
F. A. Beland, M. I. Churchwell, D. R. Doerge, D. R. Parkin, D. Malejka-Giganti, A. Hewer, D. H. Phillips, P. L. Carmichael, G. Gamboa da Costa, and M. M. Marques
Electrospray Ionization-Tandem Mass Spectrometry and 32P-Postlabeling Analyses of Tamoxifen-DNA Adducts in Humans
J Natl Cancer Inst, July 21, 2004; 96(14): 1099 - 1104.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Shibutani, N. Suzuki, Y. R. S. Laxmi, L. J. Schild, R. L. Divi, A. P. Grollman, and M. C. Poirier
Identification of Tamoxifen-DNA Adducts in Monkeys Treated with Tamoxifen
Cancer Res., August 1, 2003; 63(15): 4402 - 4406.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Yadollahi-Farsani, D. S. Davies, and A. R. Boobis
The mutational signature of {alpha}-hydroxytamoxifen at Hprt locus in Chinese hamster cells
Carcinogenesis, November 1, 2002; 23(11): 1947 - 1952.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
T. Chen, G. Gamboa da Costa, M.M. Marques, S. D. Shelton, F. A. Beland, and M. G. Manjanatha
Mutations induced by {alpha}-hydroxytamoxifen in the lacI and cII genes of Big Blue transgenic rats
Carcinogenesis, October 1, 2002; 23(10): 1751 - 1758.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
R. L. Divi, Y. P. Dragan, H. C. Pitot, and M. C. Poirier
Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen
Carcinogenesis, October 1, 2001; 22(10): 1693 - 1699.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
G. Gamboa da Costa, L.P. McDaniel-Hamilton, R. H. Heflich, M.M. Marques, and F. A. Beland
DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives
Carcinogenesis, August 1, 2001; 22(8): 1307 - 1315.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
P. W. Fan and J. L. Bolton
Bioactivation of Tamoxifen to Metabolite E Quinone Methide: Reaction with Glutathione and DNA
Drug Metab. Dispos., June 1, 2001; 29(6): 891 - 896.
[Abstract] [Full Text]


Home page
CarcinogenesisHome page
D. H. Phillips
Understanding the genotoxicity of tamoxifen?
Carcinogenesis, June 1, 2001; 22(6): 839 - 849.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Shibutani, A. Ravindernath, I. Terashima, N. Suzuki, Y. R. Santosh Laxmi, Y. Kanno, M. Suzuki, T. I. Apak, J. J. Sheng, and M. W. Duffel
Mechanism of Lower Genotoxicity of Toremifene Compared with Tamoxifen
Cancer Res., May 1, 2001; 61(10): 3925 - 3931.
[Abstract] [Full Text]


Home page
CarcinogenesisHome page
I. N.H. White, P. Carthew, R. Davies, J. Styles, K. Brown, J. E. Brown, L. L. Smith, and E. A. Martin
Short-term dosing of {{alpha}}-hydroxytamoxifen results in DNA damage but does not lead to liver tumours in female Wistar/Han rats
Carcinogenesis, April 1, 2001; 22(4): 553 - 557.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
D. J. Boocock, J. L. Maggs, K. Brown, I. N.H. White, and B.K. Park
Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of {alpha}-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts
Carcinogenesis, October 1, 2000; 21(10): 1851 - 1858.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
A. Umemoto, Y. Monden, M. Suwa, Y. Kanno, M. Suzuki, C.-X. Lin, Y. Ueyama, Md.A. Momen, A. Ravindernath, S. Shibutani, et al.
Identification of hepatic tamoxifen-DNA adducts in mice: {alpha}-(N2-deoxyguanosinyl)tamoxifen and {alpha}-(N2-deoxyguanosinyl)tamoxifen N-oxide
Carcinogenesis, September 1, 2000; 21(9): 1737 - 1744.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S. Shibutani, A. Ravindernath, N. Suzuki, I. Terashima, S. M. Sugarman, A. P. Grollman, and M. L. Pearl
Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen
Carcinogenesis, August 1, 2000; 21(8): 1461 - 1467.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Shibutani, J. T. Reardon, N. Suzuki, and A. Sancar
Excision of Tamoxifen-DNA Adducts by the Human Nucleotide Excision Repair System
Cancer Res., May 1, 2000; 60(10): 2607 - 2610.
[Abstract] [Full Text]


Home page
CarcinogenesisHome page
H. Bartsch, D. H. Phillips, J. Nair, A. Hewer, G. Meyberg-Solomeyer, and E.-M. Grischke
Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients
Carcinogenesis, April 1, 2000; 21(4): 845 - 847.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. L. Divi, M. R. Osborne, A. Hewer, D. H. Phillips, and M. C. Poirier
Tamoxifen-DNA Adduct Formation in Rat Liver Determined by Immunoassay and 32P-Postlabeling
Cancer Res., October 1, 1999; 59(19): 4829 - 4833.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
D. H. Phillips, A. Hewer, M. N. Horton, K. J. Cole, P. L. Carmichael, W. Davis, and M. R. Osborne
N-Demethylation accompanies {alpha}-hydroxylation in the metabolic activation of tamoxifen in rat liver cells
Carcinogenesis, October 1, 1999; 20(10): 2003 - 2009.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
K. Brown, R. T. Heydon, R. Jukes, I. N.H. White, and E. A. Martin
Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen
Carcinogenesis, October 1, 1999; 20(10): 2011 - 2016.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
I. N.H. White
The tamoxifen dilemma
Carcinogenesis, July 1, 1999; 20(7): 1153 - 1160.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
R. Davies, T. W. Gant, L. L. Smith, and J. A. Styles
Tamoxifen induces G:C->T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 5'-CpG-3' dinucleotide sequences as found in the lacI transgene
Carcinogenesis, July 1, 1999; 20(7): 1351 - 1356.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
V. C. Jordan and M. Morrow
Tamoxifen, Raloxifene, and the Prevention of Breast Cancer
Endocr. Rev., June 1, 1999; 20(3): 253 - 278.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
I. Terashima, N. Suzuki, and S. Shibutani
Mutagenic Potential of {{alpha}}-(N2-Deoxyguanosinyl)tamoxifen Lesions, the Major DNA Adducts Detected in Endometrial Tissues of Patients Treated with Tamoxifen
Cancer Res., May 1, 1999; 59(9): 2091 - 2095.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
F. A. Beland, L. P. McDaniel, and M. M. Marques
Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo
Carcinogenesis, March 1, 1999; 20(3): 471 - 477.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. R. Osborne, A. Hewer, W. Davis, A. J. Strain, A. Keogh, I. R. Hardcastle, and D. H. Phillips
Idoxifene derivatives are less reactive to DNA than tamoxifen derivatives, both chemically and in human and rat liver cells
Carcinogenesis, February 1, 1999; 20(2): 293 - 297.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
H. Rajaniemi, I. Rasanen, P. Koivisto, K. Peltonen, and K. Hemminki
Identification of the major tamoxifen–DNA adducts in rat liver by mass spectroscopy
Carcinogenesis, February 1, 1999; 20(2): 305 - 309.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
D. J. Boocock, J. L. Maggs, I. N.H. White, and B. K. Park
{alpha}-Hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: identification and quantification in vivo and in vitro
Carcinogenesis, January 1, 1999; 20(1): 153 - 160.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
J. I. Macgregor and V. C. Jordan
Basic Guide to the Mechanisms of Antiestrogen Action
Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1996 by the American Association for Cancer Research.